Company Overview and News
TCF Financial (TCF - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
TCB TCB-B TCF TCB-C
Investors with an interest in Banks - Midwest stocks have likely encountered both TCF Financial (TCF - Free Report) and First Interstate BancSystem (FIBK - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
TCB TCB-B TCF FIBK TCB-C
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
TCB TCB-B TCF TCB-C
ASHEVILLE, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- The board of directors of HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank” or “HTB”), today announced that C. Hunter Westbrook will assume the position of Senior Executive Vice President and Chief Operating Officer of both the Company and the Bank effective October 1, 2018. Mr. Westbrook joined HTB in 2012 as Chief Banking Officer and in his new role will also be responsible for credit administration and information technology departments.
TCB TCB-B TCF TCB-C HTBI
Santander Consumer USA Holdings Inc. (SC - Free Report) has accepted the Consumer Financial Protection Bureau’s (CFPB) accusations that the former misguided its consumers by not disclosing certain essential stipulations of the company’s auto loans and insurance policies. This news was reported by Reuters citing persons familiar with the matter. The company, which is a unit of Banco Santander, S.A. (SAN - Free Report) , has agreed to pay a fine to settle the CFPB’s claim.
WFCNP TCB TCF SANT TCB-B TCB-C SAN WFC SC BNC
Shares of TCF Financial Corporation (TCF - Free Report) climbed 1.87% in single-day trading following the second-quarter 2018 earnings release on Jul 27, before the market opened. The company reported adjusted earnings per share of 49 cents, beating the Zacks Consensus Estimate of 47 cents. Further, the figure compares favorably with the prior-year quarter figure of 33 cents. The company witnessed top-line strength in the reported quarter.
TCB ALGN TCF PBCT SAH CFG CFIN STI TCB-B CIWV STI-A TCB-C
2018-07-27 seekingalpha - 1
Good morning, everyone, and welcome to TCF’s 2018 Second Quarter Earnings Call. My name is Jamie, and I will be your conference operator today. [Operator Instructions] Please also note today’s conference call is being recorded.
WFCNP TCB TCF TCB-B LB TCB-C MS WFC
TCF Financial (TCF - Free Report) just came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.
TCB TCB-B TCF NVR TCB-C TRN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TCB / TCF Financial Corp. on message board site Silicon Investor.
as of ET